Image Place holder

Julie Hallanger-Johnson, MD

Program Leader, Endocrine Oncology Program

Specialty: Endocrinology
Program: Endocrine Oncology

Call 1-888-MOFFITT

Call 1-888-MOFFITT

Locations: Moffitt Cancer Center

Cancer Types Treated: Adrenal Carcinoma, Adrenal nodules/adrenal mass, Pituitary macroadenoma, Pituitary microadenoma, Pituitary neoplasm, Thyroid Cancer , Thyroid nodules

Dr. Julie Hallanger-Johnson is an Endocrinologist and Program Leader in the Department of Head and Neck-Endocrine Oncology at Moffitt Cancer Center. Dr. Hallanger-Johnson received her MD degree from the University of North Dakota School of Medicine. She completed an Internal Medicine Residency and Fellowship in Endocrinology and Metabolism at Mayo Clinic, Graduate School of Medicine in Rochester, MN. She then was a Clinical Assistant Professor of Medicine at the University of North Dakota, Grand Forks, ND. Dr. Hallanger-Johnson is a Clinical Educator Endocrinologist, with a particular interest in thyroid nodules and thyroid cancer. She has extensive experience in the diagnosis and evaluation of thyroid disease, and carries the Endocrine Certification in Neck Ultrasound (ECNU). Dr. Hallanger-Johnson is interested in the use of molecular markers and ultrasound information to guide decision-making in the evaluation of thyroid nodules, and the corresponding clinical outcomes research. She is also interested in systems improvement by creating timely and efficient pathways for patient care. 

Education & Training

Board Certification:

  • Endocrinology, Diabetes & Metabolism
  • Internal Medicine


  • Mayo Graduate School of Medicine - Endocrinology and Metabolism


  • Mayo Graduate School of Medicine - Internal Medicine

Medical School:

  • University of North Dakota School of Medicine and Health Sciences - MD
Participating Trials

Multicenter, Open-label, Phase 1, Dose-escalation,Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: KHK2455; KW-0761 (Mogamulizumab); Mogamulizumab

Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer
Condition: Head & Neck
Intervention: BAY 43-9006 (Sorafenib); Cabozantinib (XL 184); E7080 (Lenvatinib); Lenvatinib (Lenvima); Sorafenib; Vandetanib

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Valderrabano P, Khazai L, Thompson ZJ, Otto KJ, Hallanger-Johnson JE, Chung CH, Centeno BA, McIver B. Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid Nodules. JAMA Otolaryngol Head Neck Surg. 2018 Sep;144(9):788-795. Pubmedid: 30027226. Pmcid: PMC6233620.
  • Valderrabano P, Khazai L, Thompson ZJ, Leon ME, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Chung CH, Centeno BA, McIver B. Impact of oncogene panel results on surgical management of cytologically indeterminate thyroid nodules. Head Neck. 2018 Aug;40(8):1812-1823. Pubmedid: 29624786.
  • Valderrabano P, Khazai L, Thompson ZJ, Sharpe SC, Tarasova VD, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Wenig BM, Chung CH, Centeno BA, McIver B. Cancer Risk Associated with Nuclear Atypia in Cytologically Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis. Thyroid. 2018 02;28(2):210-219. Pubmedid: 29160163.
  • Valderrabano P, Khazai L, Leon ME, Thompson ZJ, Ma Z, Chung CH, Hallanger-Johnson JE, Otto KJ, Rogers KD, Centeno B, McIver B. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology. Endocr Relat Cancer. 2017 Mar;24(3):127-136. Pubmedid: 28104680.
  • Valderrabano P, Khazai L, Thompson ZJ, Leon ME, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Wenig BM, Chung CH, Centeno BA, McIver B. Cancer Risk Stratification of Indeterminate Thyroid Nodules: A Cytological Approach. Thyroid. 2017 10;27(10):1277-1284. Pubmedid: 28806881. Pmcid: PMC6112164.
  • Reddi HV, Driscoll CB, Madde P, Milosevic D, Hurley RM, McDonough SJ, Hallanger-Johnson J, McIver B, Eberhardt NL. Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy. Cancer Gene Ther. 2013 May;20(5):267-275. Pubmedid: 23598436.
  • Khoo TK, Baker CH, Hallanger-Johnson J, Tom AM, Grant CS, Reading CC, Sebo TJ, Morris JC. Comparison of ultrasound-guided fine-needle aspiration biopsy with core-needle biopsy in the evaluation of thyroid nodules. Endocr Pract. 2008 May;14(4):426-431. Pubmedid: 18558594.
  • Hallanger Johnson JE, Kearns AE, Doran PM, Khoo TK, Wermers RA. Fluoride-related bone disease associated with habitual tea consumption. Mayo Clin Proc. 2007 Jun;82(6):719-724. Pubmedid: 17550752.